Drugs / DREPAGLOBE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03964792 | Nov 2019 → Jul 2022 | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DREPAGLOBE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03964792 ↗ |
| Route | Intravenous | “Each patient will receive a single IV infusion of DREPAGLOBE drug product” NCT03964792 ↗ |